TVM Capital MENA Ltd. is a private equity and growth capital firm focused on investments in the healthcare markets of the Middle East, North Africa (MENA) and India. The firm, based at the Dubai International Financial Center (DIFC), Dubai, United Arab Emirates, is licensed and regulated under the Dubai Financial Services Authority (DFSA).
The team of TVM Capital MENA is affiliated to of the international Life Science Practice of TVM Capital. A global leader in the financing of life science growth companies, the TVM Capital Life Science Practice currently manages € 820 million (US$1.2bn) of committed capital. The investment professionals draw upon the experience, international approach and demonstrated success of about 80 exits from alsmost 120 investments. Exits include nearly 40 initial public offerings on the NASDAQ, and the London, Frankfurt, Zurich and Vienna Stock Exchanges and 25 trade sales and mergers. The team combines long-standing international investment experience and operating track records with extensive networks in and knowledge of the MENA region.
Value Creation as Key Differentiator
Our deep understanding of the healthcare industry, especially the pharmaceutical value chain (encompassing drug discovery and development, regulatory approval and commercialization) and healthcare services is a core aspect of how we add value to investments in the MENA region. The unique combination of company development skills and international growth strategies attracts attention among established companies and new market entrants alike. Our proven and documented expertise is a strong motivator for generalist private equity funds as well as the healthcare providers and pharmaceutical to approach us for financings. Of particular note are:
- A team of highly experienced investment professionals
- A hands-on approach to deal making as an active investor
- Professional dedication to the implementation of world-class corporate governance structures in our portfolio companies: at the management and board levels, in financial controls as well as strategy and operations
- Our connections and access to products, management, board members and capital throughout the Western markets derived from almost 25 years of investing in our key target market, more than 100 investments and more than 40 active portfolio companies in the sector in Europe and the U.S.
- The stamina and patience we believe is required to be a good ‘strategic partner’ for portfolio companies
- Our capabilities to manage the opportunities in up-markets as well as the challenges in market downturns, as proven by our long-term performance across major cycles in our industry between 1985 and today
- Our capabilities as a specialist pharmaceutical and healthcare ‘connector’ of the local industry and private equity players as well as local investment banks with the European and U.S. healthcare operators and pharmaceutical